Anticoagulation in Acute Neurological Disease

Abstract

While anticoagulation and its reversal have been of clinical relevance for decades, recent academic and technological advances have expanded the repertoire of its application in neurological disease. The advent of direct oral anticoagulants provides effective, mechanistically elegant, and relatively safer therapeutic options than warfarin for eligible patients at risk for neurological sequelae of prothrombotic states, particularly given the recent availability of corresponding reversal agents. In this review, we examine the provenance, indications, safety, and reversal tools for anticoagulant medications in the context of neurological disease, with specific attention to acute ischemic stroke, cerebral venous sinus thrombosis, and intracerebral hemorrhage. We will use specific clinical scenarios to illustrate the complex factors that must be considered in the use of anticoagulation, including intracranial pathology such as intracerebral hemorrhage, traumatic brain injury, or malignancy; metabolic complications such as chronic kidney disease; pregnancy; and advanced age.

Keywords

atrial fibrillation - intracerebral hemorrhage - reversal agents - oral anticoagulant

Publikationsverlauf

Artikel online veröffentlicht:
07. Oktober 2021

• References

• 1 Franchini M, Liumbruno GM, Bonfanti C, Lippi G. The evolution of anticoagulant therapy. Blood Transfus 2016; 14 (02) 175-184
• 2 Levine M, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy for ischemic cerebral vascular disease. Stroke 1986; 17 (01) 111-116
• 3 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
• 4 van Asch CJJ, Luitse MJA, Rinkel GJE, van der Tweel I, Algra A, Klijn CJM. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9 (02) 167-176
• 5 Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013; 112 (08) 1142-1147
• 6 Investigators AF. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154 (13) 1449-1457
• 7 Albers GW, Diener H-C, Frison L. et al; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293 (06) 690-698
• 8 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 9 Connolly SJ, Eikelboom J, Joyner C. et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
• 10 Granger CB, Alexander JH, McMurray JJV. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
• 11 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
• 12 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
• 13 Lip GYH, Keshishian A, Li X. et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke 2018; 49 (12) 2933-2944
• 14 Macha K, Marsch A, Siedler G. et al. Cerebral ischemia in patients on direct oral anticoagulants. Stroke 2019; 50 (04) 873-879
• 15 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74 (01) 104-132
• 16 Mohr JP, Thompson JL, Lazar RM. et al; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345 (20) 1444-1451
• 17 Diener H-C, Sacco RL, Easton JD. et al; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380 (20) 1906-1917
• 18 Hart RG, Sharma M, Mundl H. et al; NAVIGATE ESUS Investigators. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378 (23) 2191-2201
• 19 Chimowitz MI, Lynn MJ, Howlett-Smith H. et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352 (13) 1305-1316
• 20 Metso TM, Metso AJ, Helenius J. et al. Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke 2007; 38 (06) 1837-1842
• 21 Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev 2011; 30 (08) CD002005
• 22 Einhäupl K, Stam J, Bousser MG. et al; European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17 (10) 1229-1235
• 23 Ferro JM, Coutinho JM, Dentali F. et al; RE-SPECT CVT Study Group. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 2019
• 24 Wintzen AR, de Jonge H, Loeliger EA, Bots GT. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984; 16 (05) 553-558
• 25 Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164 (08) 880-884
• 26 Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2015; 13 (11) 2012-2020
• 27 Gerner ST, Kuramatsu JB, Sembill JA. et al. Characteristics in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Stroke 2019; 50 (06) 1392-1402
• 28 Kaiser J, Schebesch KM, Brawanski A, Linker RA, Schlachetzki F, Wagner A. Long-term follow-up of cerebral amyloid angiopathy-associated intracranial hemorrhage reveals a high prevalence of atrial fibrillation. J Stroke Cerebrovasc Dis 2019; 28 (11) 104342
• 29 Murthy SB, Díaz I, Wu X. et al. Risk of arterial ischemic events after intracerebral hemorrhage. Stroke 2020; 51 (01) 137-142
• 30 Murphy MP, Kuramatsu JB, Leasure A. et al. Cardioembolic stroke risk and recovery after anticoagulation-related intracerebral hemorrhage. Stroke 2018; 49 (11) 2652-2658
• 31 Murthy SB, Gupta A, Merkler AE. et al. Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke 2017; 48 (06) 1594-1600
• 32 Biffi A, Kuramatsu JB, Leasure A. et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol 2017; 82 (05) 755-765
• 33 Charidimou A, Shoamanesh A, Al-Shahi Salman R. et al. Cerebral amyloid angiopathy, cerebral microbleeds and implications for anticoagulation decisions: the need for a balanced approach. Int J Stroke 2018; 13 (02) 117-120
• 34 Pennlert J, Overholser R, Asplund K. et al. Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke 2017; 48 (02) 314-320
• 35 Charidimou A, Boulouis G, Greenberg SM, Viswanathan A. Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: a meta-analysis. Neurology 2019; 93 (24) e2192-e2202
• 36 Martí-Fàbregas J, Medrano-Martorell S, Merino E. et al; HERO Study Investigators. MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation. Neurology 2019; 92 (21) e2432-e2443
• 37 Perreault S, Côté R, White-Guay B, Dorais M, Oussaïd E, Schnitzer ME. Anticoagulants in older patients with nonvalvular atrial fibrillation after intracranial hemorrhage. J Stroke 2019; 21 (02) 195-206
• 38 Silva RMFLD, Miranda CM, Liu T, Tse G, Roever L. Atrial fibrillation and risk of dementia: epidemiology, mechanisms, and effect of anticoagulation. Front Neurosci 2019; 13: 18
• 39 Paciaroni M, Agnelli G, Falocci N. et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke 2015; 46 (08) 2175-2182
• 40 Seiffge DJ, Paciaroni M, Wilson D. et al; CROMIS-2, RAF, RAF-DOAC, SAMURAI, NOACISP LONGTERM, Erlangen and Verona Registry Collaborators. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol 2019; 85 (06) 823-834
• 41 Altavilla R, Caso V, Bandini F. et al. Anticoagulation after stroke in patients with atrial fibrillation. Stroke 2019; 50 (08) 2093-2100
• 42 Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 2018; 49 (01) 98-106
• 43 Franko J, Kish KJ, O'Connell BG, Subramanian S, Yuschak JV. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma 2006; 61 (01) 107-110
• 44 Zeeshan M, Jehan F, O'Keeffe T. et al. The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI. J Trauma Acute Care Surg 2018; 85 (05) 915-920
• 45 Kobayashi L, Barmparas G, Bosarge P. et al; AAST Multicenter Prospective Observational Study of Trauma Patients on Novel Oral Anticoagulants Study Group. Novel oral anticoagulants and trauma: the results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial. J Trauma Acute Care Surg 2017; 82 (05) 827-835
• 46 Carney BJ, Uhlmann EJ, Puligandla M. et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost 2019; 17 (01) 72-76
• 47 Tarlov N, Norbash AM, Nguyen TN. The safety of anticoagulation in patients with intracranial aneurysms. J Neurointerv Surg 2013; 5 (05) 405-409
• 48 Malhotra K, Ishfaq MF, Goyal N. et al. Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis. Neurology 2019; 92 (21) e2421-e2431
• 49 Makani A, Saba S, Jain SK. et al. Safety and efficacy of direct oral anticoagulants versus warfarin in patients with chronic kidney disease and atrial fibrillation. Am J Cardiol 2020; 125 (02) 210-214
• 50 James AH. Pregnancy and thrombotic risk. Crit Care Med 2010; 38 (2, Suppl): S57-S63
• 51 Scott CA, Bewley S, Rudd A. et al. Incidence, risk factors, management, and outcomes of stroke in pregnancy. Obstet Gynecol 2012; 120 (2, Pt 1): 318-324
• 52 James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106 (03) 509-516
• 53 Yoshida K, Takahashi JC, Takenobu Y, Suzuki N, Ogawa A, Miyamoto S. Strokes associated with pregnancy and puerperium: a nationwide study by the Japan Stroke Society. Stroke 2017; 48 (02) 276-282
• 54 Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370 (14) 1307-1315
• 55 Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res 2018; 169: 123-127
• 56 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M. et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019; 171 (10) 685-694
• 57 Cohen H, Hunt BJ, Efthymiou M. et al; RAPS Trial Investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016; 3 (09) e426-e436
• 58 Hemphill III JC, Greenberg SM, Anderson CS. et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46 (07) 2032-2060
• 59 Mayer SA, Brun NC, Begtrup K. et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352 (08) 777-785
• 60 Shields RC, McBane RD, Kuiper JD, Li H, Heit JA. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 2001; 76 (03) 260-266
• 61 Frontera JA, Lewin III JJ, Rabinstein AA. et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. a statement for healthcare professionals from the Neurocritical Care Society and the Society of Critical Care Medicine. Crit Care Med 2016; 44 (12) 2251-2257
• 62 Sarode R, Milling Jr TJJ, Refaai MA. et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128 (11) 1234-1243
• 63 Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002; 108 (01) 25-30
• 64 Goldstein JN, Thomas SH, Frontiero V. et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37 (01) 151-155
• 65 Frontera JA, Gordon E, Zach V. et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care 2014; 21 (03) 397-406
• 66 Fredriksson K, Norrving B, Strömblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23 (07) 972-977
• 67 Pollack Jr CV, Reilly PA, Eikelboom J. et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
• 68 Rogers KC, Finks SW. A new option for reversing the anticoagulant effect of factor Xa inhibitors: andexanet alfa (ANDEXXA). Am J Med 2019; 132 (01) 38-41
• 69 Cuker A, Burnett A, Triller D. et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. Am J Hematol 2019; 94 (06) 697-709
• 70 Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants. Basic and translational research in intracerebral hemorrhage: limitations, priorities, and recommendations. Stroke 2018; 49 (05) 1308-1314
• 71 Koch AW, Schiering N, Melkko S. et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood 2019; 133 (13) 1507-1516
• 72 Kamel H, Longstreth Jr WT, Tirschwell DL. et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods. Int J Stroke 2019; 14 (02) 207-214
• 73 Shoamanesh A, Charidimou A, Sheth KN. Comorbid atrial fibrillation in cerebral amyloid angiopathy-related intracerebral hemorrhage: between a rock and a hard place. J Stroke Cerebrovasc Dis 2019; 28 (11) 104351